News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- The Importance of Regulatory Due Diligence During the Acquisition Process
Changing Landscape of Evidence Charting New Assessment Pathways: Q&A with Canadian Agency for Drugs and Technologies in Health (CADTH) CEO Suzanne McGurn
Global Forum discusses the concept of HTA and its place in the therapeutic development of pipeline products—first on a global basis and then within the context of Canadian and other international jurisdictions—with Suzanne McGurn, president and chief executive officer of the Canadian Agency for Drugs and Technologies in Health (CADTH).
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!